Loading clinical trials...
Loading clinical trials...
A Phase One/Two Clinical Trial on the Use of Autograft Mesenchymal Stem Cells Differentiated Into Progenitor of Hepatocytes for the Salvage Treatment of Patients With End-stage Liver Disease
The methods for separation of mesenchymal stem cell were established in 2001. These cells can differentiate to osteocytes, hepatocytes, chondrocytes, myocytes and etc,. In this study the investigators try to separate mesenchymal stem cell from end stage liver disease, then these cells will be differentiated to progenitor of hepatocytes, finally , the investigators injected these cells into portal vein under ultrasound guide. The investigators determine the effects of injected cells in reestablishment of liver function.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Research Center for Gastroenterology and Liver Diseases
Tehran, Tehran Province, Iran
Research center of Gastroenterology and Liver Disease
Tehran, Tehran Province, Iran
Start Date
February 1, 2006
Primary Completion Date
May 1, 2009
Completion Date
June 1, 2009
Last Updated
September 17, 2009
30
ESTIMATED participants
injection of progenitor of hepatocyte drived from Mesenchymal stem cell
PROCEDURE
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Collaborators
NCT05597488
NCT06932783
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06306963